Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia (LA-PBMC)
Primary Purpose
Familial Hypercholesterolemia
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Pre-lipid apheresis
Post-lipid apheresis
Sponsored by
About this trial
This is an interventional treatment trial for Familial Hypercholesterolemia
Eligibility Criteria
Inclusion Criteria:
- Homozygotes for familial hypercholesterolemia who receive lipid apheresis
- Aged between 18-60 years
Exclusion Criteria:
- Smokers (> 1 cigarette/day)
- Subjects with a previous history of cardiovascular disease
- Subjects with type 2 diabetes
- Subjects with a monogenic dyslipidemia that it is not homozygote for familial hypercholesterolemia
- Subjects with endocrine or gastrointestinal disorders
- History of alcohol or drug abuse within the past 2 years
- Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
Sites / Locations
- Institute of Nutrition and Functional Foods (INAF)
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Pre-lipid apheresis
Post-lipid apheresis
Arm Description
Blood samples will be taken just before the start of the lipid apheresis treatment.
Blood samples will be taken following the lipid apheresis treatment.
Outcomes
Primary Outcome Measures
Change in mRNA expression of genes involved in cardiovascular disease using microarrays analysis.
Secondary Outcome Measures
Change in serum levels of C-reactive protein
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02462655
Brief Title
Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia
Acronym
LA-PBMC
Official Title
Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia
Study Type
Interventional
2. Study Status
Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
October 2015 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
February 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Laval University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Familial hypercholesterolemia (FH) is an autosomal codominant single-gene disorder caused by mutations in the LDL receptor gene that disrupt the normal clearance of LDL particles from the plasma compartment. Heterozygous patients present a 2- to 3-fold raise in plasma LDL-cholesterol (C) concentrations, tendinous xanthomatosis and premature atherosclerotic coronary heart disease (CHD), usually occurring between the age of 35 and 55 years. Since the mid-1970s, LDL-C has been removed from the blood of patients using plasmapheresis, and this technique has been shown to improve the life expectancy of FH homozygotes. LDL apheresis selectively removes LDL particles but not immunoglobulins and other beneficial proteins, thereby overcoming a potential drawback of the traditional plasmapheresis method. LDL-C is effectively reduced by more than 60% immediately after LDL apheresis, although LDL levels rebound rapidly.
Dextran sulfate adsorption is a commonly apheresis technique used in familial hypercholesterolemia patients. In this apheresis plasma is separated from red blood cells and passed over columns of cellulose beads containing dextran sulfate which binds apolipoprotein B (apoB) by a highly selective electrostatic binding mechanism. Since LDL, very-low density lipoprotein (VLDL), and Lipoprotein (a) all contain apoB, dextran sulfate adsorption apheresis selectively reduces these lipoproteins while having little effect on the non-apoB containing HDL particles. In clinical practice, LDL apheresis reduces the rate of future cardiovascular events and has been postulated to have additional effects on potentially pro-atherogenic factors. Some proteins have been identified with adhesive characteristics to lipoproteins, rheological, immunological and inflammation relevant proteins16-19 that influence microcirculation as well as the inflammatory response. However, no studies have yet to investigate the impact of LDL apheresis on the expression of different genes involved in cardiovascular disease.
The main objective of the present research project is to investigate the impact of the LDL apheresis dextran sulfate adsorption system on the messenger ribonucleic acid (mRNA) expression of genes involved in cardiovascular disease using microarrays analysis in 9 FH homozygotes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Familial Hypercholesterolemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
9 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Pre-lipid apheresis
Arm Type
Experimental
Arm Description
Blood samples will be taken just before the start of the lipid apheresis treatment.
Arm Title
Post-lipid apheresis
Arm Type
Experimental
Arm Description
Blood samples will be taken following the lipid apheresis treatment.
Intervention Type
Other
Intervention Name(s)
Pre-lipid apheresis
Intervention Description
Blood samples will be taken just before the start of the lipid apheresis treatment.
Intervention Type
Other
Intervention Name(s)
Post-lipid apheresis
Intervention Description
Blood samples will be taken following the lipid apheresis treatment.
Primary Outcome Measure Information:
Title
Change in mRNA expression of genes involved in cardiovascular disease using microarrays analysis.
Time Frame
Pre-lipid apheresis (t=0h) and post-lipid apheresis (t=3h)
Secondary Outcome Measure Information:
Title
Change in serum levels of C-reactive protein
Time Frame
Pre-lipid apheresis (t=0h) and post-lipid apheresis (t=3h)
Other Pre-specified Outcome Measures:
Title
Change in serum levels of vascular cell adhesion molecule
Time Frame
Pre-lipid apheresis (t=0h) and post-lipid apheresis (t=3h)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Homozygotes for familial hypercholesterolemia who receive lipid apheresis
Aged between 18-60 years
Exclusion Criteria:
Smokers (> 1 cigarette/day)
Subjects with a previous history of cardiovascular disease
Subjects with type 2 diabetes
Subjects with a monogenic dyslipidemia that it is not homozygote for familial hypercholesterolemia
Subjects with endocrine or gastrointestinal disorders
History of alcohol or drug abuse within the past 2 years
Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Couture, MD,FRCP,PhD
Organizational Affiliation
Laval University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institute of Nutrition and Functional Foods (INAF)
City
Quebec
ZIP/Postal Code
G1V 0A6
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia
We'll reach out to this number within 24 hrs